Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

CDC Advisers Consider Boosters for Immune-Compromised Americans

Julie Steenhuysen  |  

CHICAGO (Reuters)—Advisers to the U.S. Centers for Disease Control & Prevention will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems. Data presented ahead of the July 22 meeting noted that people with compromised immune systems have a reduced antibody response following the recommended primary…

Learn to Share Your Voice at Advocacy 101

  |  

Applications are now open for the ACR’s Advocacy 101 program, held in conjunction with Advocates for Arthritis. Amanda Schnell, MD, describes how ACR/ARP members can learn to be successful advocates for rheumatology.

2022 Physician Fee Schedule Proposed Rule Released

  |  

In the proposed rule released July 13, the ACR is encouraged by the continued implementation of evaluation and management reimbursement adjustments to better reflect the work and expertise needed to treat complex patient populations, the extension of many telehealth flexibilities and the inclusion of the ACR’s proposed MACRA MIPS Value Pathway for rheumatology.

Guselkumab Promising for Psoriatic Arthritis with Axial Symptoms

Lorraine L. Janeczko  |  

NEW YORK (Reuters Health)—Guselkumab may be effective in patients who have psoriatic arthritis (PsA) with axial symptoms, a post-hoc analysis of data from two randomized controlled trials suggests.1 “Because PsA is a heterogeneous disease that manifests as various symptoms, treatment choices should involve consideration of all relevant domains of disease for each individual patient,” researchers…

Tocilizumab After Ultra-Short Course Steroids Promising for Newly Diagnosed GCA

Marilynn Larkin  |  

NEW YORK (Reuters Health)—Tocilizumab induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows.1 His early research on cytokines and glucocorticoids led Peter Villiger, MD, of Medical Center Monbijou, Bern, Switzerland, to find ways to reduce steroid use, he…

Generally Favorable Outcomes 6 Months After COVID-Linked Inflammatory Syndrome in Kids

Reuters Staff  |  

NEW YORK (Reuters Health)—A six-month assessment of children with pediatric inflammatory multisystem syndrome temporally associated with COVID-19 disease (PIMS-TS) show generally favorable outcomes, but also a range of lingering issues. Cardiac, gastrointestinal, renal, hematology and otolaryngology problems largely resolved at six months, but muscular fatigue and emotional lability were common. Long-term, serious end-organ damage occurred…

U.S. to Announce New Warning on J&J Coronavirus Vaccine for Guillain-Barré Syndrome

Reuters Staff  |  

(Reuters)—The U.S. Food & Drug Administration (FDA) is expected to announce a new warning on Johnson & Johnson’s (J&J’s) coronavirus vaccine related to a rare autoimmune disorder, The Washington Post reported on Monday, citing four people familiar with the matter.1 According to The Post, about 100 preliminary reports of Guillain-Barré syndrome have been detected in the…

Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination

Linda Carroll  |  

(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1 A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who…